J.P. Morgan Healthcare Conference Presentation
Improving cancer survival and quality of life
Initial focus on hematologic malignancies and gynaecologic cancers
.
Jemperli (dostarlimab)
Ambition to be the backbone of
our ongoing immuno-oncology
research
Combination treatment in
endometrial cancer approved
in US, EU with part one data to
be presented in 2024 and
positive part 2 data in house;
monotherapy data is expected
in 2027
Combination treatment with
cobolimab, an anti-TIM3, in
NSCLC, data expected 2024
Treatment in rectal cancer,
data expected in 2027
•
Ojjaara (momelotinib)
Approved in the US as the first
and only treatment indicated
for MF2 patients with anaemia
Nearly all MF patients are
estimated to develop anaemia
EU marketing authorisation
expected early 2024
Potential to become a
backbone therapy in MF due to
differentiated MOA
Combinations and future
indications under evaluation
•
Zejula (niraparib)
Assessing activity across
multiple tumour types and in
combination with other
therapeutics
Combination treatment in
endometrial cancer positive
data in house
Combination treatment in
ovarian cancer, data expected
in 2024
Maintenance treatment in
ovarian cancer, data expected
in 2024
Maintenance treatment in
NSCLC, data expected in 2024
Additional pipeline assets
Exclusive license agreements
with Hansoh for two novel
antibody-drug conjugates for
gynaecologic cancers and
broader solid tumour
indications
Blenrep positive headline results
for DREAMM-7 in second-line
treatment for RRMM3;
DREAMM-8 data in H2 2024
Cobolimab, an anti-TIM3
antagonist in phase III in
combination with Jemperli for
treatment of NSCLC
Exploring novel combinations
that act on all major targets of
the CD226 axis; blocking these
may help the immune system
better target tumour cells
GSK
1. Non-small cell lung cancer
2. Myelofibrosis 3. Relapse or refractory multiple myelomaView entire presentation